RPRX Royalty Pharma plc: institutional ownership and insider trading
697 funds reported holding $21.2B of Royalty Pharma plc in their latest 13F filings; in Q2 2026 funds net bought $668M, with 98 new positions and 44 funds selling out; over the last 12 months insiders bought $0 and sold $92.8M on the open market; over its last four quarters it reported revenue of $2.54B and net income of $812M.
RPRX revenue and earnings
- Quarter ended Jun 30, 2026: revenue $674M, net income $17.9M, EPS 0.04
- Quarter ended Mar 31, 2026: revenue $631M, net income $295M, EPS 0.67
- Quarter ended Dec 31, 2025: revenue $622M, net income $211M, EPS 0.49
- Quarter ended Sep 30, 2025: revenue $609M, net income $288M, EPS 0.67
Famous investors holding RPRX
- Renaissance Technologies (Renaissance Technologies): $109M, 0.2% of the portfolio
- Two Sigma (Two Sigma Investments): $164M, 0.1% of the portfolio
- Ray Dalio (Bridgewater Associates): $12.3M, 0.1% of the portfolio
- Ken Griffin (Citadel Advisors): $89.2M, 0.0% of the portfolio
- D. E. Shaw (D. E. Shaw & Co.): $29.4M, 0.0% of the portfolio
- Izzy Englander (Millennium Management): $1.06M, 0.0% of the portfolio
Largest institutional holders of RPRX
- MORGAN STANLEY (MS, MS-PA, MS-PE, MS-PF, MS-PI, MS-PK, MS-PL, MS-PO, MS-PP, MS-PQ) — $2.41B
- Capital International Investors — $1.98B
- BlackRock, Inc. (BLK) — $1.56B
- FMR LLC — $1.37B
- STATE STREET CORP (STT, STT-PG) — $692M
- PRICE T ROWE ASSOCIATES INC /MD/ — $628M
- Swedbank AB — $601M
- BAILLIE GIFFORD & CO — $562M
- Capital World Investors — $534M
- GEODE CAPITAL MANAGEMENT, LLC — $451M
Recent RPRX insider trades
- Oct 5, 2026: Urist Marshall sold 4,126 shares ($236K)
- Sep 28, 2026: Urist Marshall sold 4,126 shares ($239K)
- Sep 22, 2026: Hite Christopher sold 100,000 shares ($5.85M)
- Aug 18, 2026: Hite Christopher sold 100,000 shares ($6.00M)
5%+ owners
- Legorreta G. Pablo: 18.7% (Schedule 13D/A, filed Aug 17, 2026)
- Capital International Investors: 8.8% (Schedule 13G/A, filed May 14, 2026)
Who owns the most RPRX stock?
The largest institutional holders of Royalty Pharma plc in the latest 13F filings are MORGAN STANLEY (MS, MS-PA, MS-PE, MS-PF, MS-PI, MS-PK, MS-PL, MS-PO, MS-PP, MS-PQ) ($2.41B), Capital International Investors ($1.98B), BlackRock, Inc. (BLK) ($1.56B).
Are insiders buying or selling RPRX?
Over the last 12 months insiders bought $0 and sold $92.8M of Royalty Pharma plc stock on the open market (SEC Form 4).
Which famous investors own RPRX?
Renaissance Technologies, Two Sigma, Ray Dalio, Ken Griffin, D. E. Shaw.
What was RPRX's revenue last quarter?
Royalty Pharma plc reported revenue of $674M for the quarter ended June 30, 2026, with net income of $17.9M.
Which ETFs hold RPRX?
53 ETFs and mutual funds hold it among their top 100 positions, including VXF, VFLO, VHGEX, IHE.